Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
160 participants
OBSERVATIONAL
2026-01-15
2026-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
NCT02687620
To Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early AS
NCT02311842
Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
NCT02132234
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
NCT01061723
Etanercept (Enbrel) in Ankylosing Spondylitis
NCT01289743
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The fact that PGRN acts by binding to TNF-α receptors, the use of TNF-α inhibitors in current treatment in patients with AS and the importance of this pathway in disease pathogenesis suggested that PGRN may be a marker associated with disease activity in these patients. In this study, we aimed to compare serum PGRN and TNF-α levels in patients with AS with healthy control group and to determine the relationship between TNF-α inhibitor use and PGRN levels in patients with AS.
In our study, 80 patients aged 20-65 years who were diagnosed with AS according to ASAS 2009 criteria and followed up in our clinic will be included. Patients with pregnancy or lactation status, acute or chronic infection findings, malignancy, and the presence of concurrent secondary rheumatic diseases other than AS will be excluded. As a healthy control group, 80 people aged 20-65 years without pregnancy or lactation, acute or chronic infection, malignancy and rheumatic disease will be recruited. Age, gender, comorbidities, duration of the disease, and medications used by all patients will be recorded. In addition, BASDAI, BASFI, BASMI, ASQoL, ASDAS-CRP, ESR, CRP levels will be recorded to determine the severity of AS clinically in the patient group. Participants in the patient and control groups will be seen at one time and serum PGRN and TNF levels will be measured by ELISA method.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with ankylosing spondylitis on TNF inhibitors
Participants will be seen at one time and serum PGRN and TNF levels will be measured from each of them by ELISA method.
No interventions assigned to this group
patients with ankylosing spondylitis taking non-steroidal anti-inflammatory drugs
Participants will be seen at one time and serum PGRN and TNF levels will be measured from each of them by ELISA method.
No interventions assigned to this group
Control
Participants will be seen at one time and serum PGRN and TNF levels will be measured from each of them by ELISA method.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signing the informed consent form
* Axial spondyloarthropathy diagnosis according to ASAS 2009 criteria
Exclusion Criteria
* Having signs of acute or chronic infection
* Presence of malignancy
* Having concurrent secondary rheumatic disease other than Axial Spondyloarthropathy
20 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi
UNKNOWN
Kirsehir Ahi Evran Universitesi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seyda Sultan Eraslan
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kırşehir Ahi Evran University
Kırşehir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Nazife Kapan, Asst. Prof.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nazife KAPAN, Asst.Prof.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AhiEvranU-FTR-ŞSE-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.